Does Ketamine Help with PTSD?

Ketamine for PTSD may reduce symptoms quickly for some people, but it is not an established first-line PTSD treatment. Small randomized trials of intravenous ketamine found improvements within days or hours, including in people with chronic PTSD. The studies are promising, yet the evidence is still limited, effects may fade, and treatment should be considered with a qualified clinician alongside proven PTSD care.

PTSD, or post-traumatic stress disorder, is a condition that can involve intrusive memories, avoidance, changes in mood and thinking, and heightened arousal after trauma. The National Institute of Mental Health describes psychotherapy and medication as established treatment options. Ketamine is commonly discussed when symptoms remain significant despite standard care, but the right next step depends on a person's history, current medications, medical risks, and access to follow-up care.

What the research shows

The first randomized controlled trial focused specifically on PTSD was published in 2014. In that studyFeder and colleagues reported in JAMA Psychiatry that participants received a single intravenous ketamine dose of 0.5 mg/kg, and PTSD symptom severity improved within 24 hours compared with the active control medication, midazolam.

A later randomized trial evaluated repeated infusions in adults with chronic PTSD. Feder and colleagues reported in 2021 that repeated ketamine infusions over two weeks were associated with greater PTSD symptom reduction than midazolam. Some benefits continued for weeks after the treatment course, but this does not show that ketamine provides lasting remission for everyone.

These trials are useful because they compare ketamine with an active control, rather than relying only on before-and-after reports. They also have limits. The studies enrolled relatively small groups, used IV treatment in structured research settings, and cannot answer every practical question about maintenance treatment, other routes of administration, or long-term outcomes.

The available research also includes people with both PTSD and depression. That overlap matters because depression can improve at the same time as PTSD symptoms. It does not mean ketamine is appropriate for every person with either condition.

Why ketamine may affect PTSD symptoms

Ketamine is an NMDA receptor antagonist, meaning it changes signaling through a glutamate receptor involved in brain communication. Researchers are studying whether these effects may support neuroplasticity, the brain's ability to change connections and responses over time.

PTSD has been associated with altered function in brain systems involved in threat detection, memory, and emotional regulation, including the amygdala, hippocampus, and prefrontal cortex. Ketamine may affect these systems, but its precise role in PTSD improvement remains under study. For a closer look at the proposed biology, see how ketamine-related neuroplasticity mechanisms are being studied.

Some clinicians and researchers are interested in whether a period of symptom relief could help a person engage in psychotherapy. That possibility is not proof that ketamine-assisted psychotherapy works for every trauma survivor, and protocols vary. Readers considering this approach can review ketamine integration therapy for questions to discuss with a treating clinician.

Who may want to discuss ketamine with a clinician

Ketamine may be a topic for discussion when PTSD symptoms remain severe after appropriate standard treatment, particularly when depression is also present. It is a conversation to have with a clinician who can review the full clinical picture, not a substitute for an evaluation.

It may be less suitable when a person cannot receive appropriate monitoring or follow-up, has a history that raises concern about dissociation or substance-related risk, or has medical factors that need specialist review. Individual circumstances matter. The VA and Department of Defense PTSD guideline recommends trauma-focused psychotherapies as first-line care and suggests against ketamine for PTSD based on the evidence reviewed in that guideline.

That recommendation does not erase the trial findings. It reflects the difference between early positive studies and the stronger, broader evidence needed to recommend a treatment routinely.

Safety questions to ask before considering treatment

Ketamine can cause short-term dissociation, changes in perception, nausea, dizziness, sleepiness, and temporary increases in blood pressure. A clinician should explain what monitoring is provided, what happens during an uncomfortable experience, and how you will get home safely after treatment.

Medication review is essential. Alcohol, sedatives, benzodiazepines, and other drugs can change safety considerations or treatment planning. Read this guide to ketamine drug interactions and bring a complete medication and supplement list to the appointment. For more on common short-term effects, see common ketamine side effects.

The bottom line

Ketamine for PTSD has shown rapid symptom reduction in several controlled studies, especially with IV treatment in clinical research settings. It remains an emerging option rather than standard first-line care. People considering it should weigh the limited long-term evidence, possible dissociative effects, medical and medication considerations, and the importance of continued trauma-focused treatment.

A good evaluation produces a clear plan: why ketamine is being considered, what established care will continue, how safety will be monitored, and how success will be assessed.